-
1.发明公开公开(公告)号：US20230346825A1
公开(公告)日：2023-11-02
申请号：US18029340
申请日：2021-09-29
Inventor： István Puskás , Abdula KURKAYEV
IPC: A61K31/724 , A61P25/28
CPC classification number: A61K31/724 , A61P25/28
Abstract: The present invention generally relates to use of single isomer chemically modified cyclodextrins, namely, S-(carboxyalkyl)-thio-cyclodextrin salts in medication used for the prevention or treatment of lysosomal storage diseases. More particularly, the present invention relates to isomer-pure, single isomer hexakis-S-(carboxyalkyl)-hexathio-alpha-cyclodextrin sodium salts, heptakis-S-(carboxyalkyl)-heptathio-beta-cyclodextrin sodium salts and octakis-S-(carboxyalkyl)-octathio-gamma-cyclodextrin sodium salts in medication used for the prevention or treatment of lysosomal storage diseases.
-
公开(公告)号：US20210145816A1
公开(公告)日：2021-05-20
申请号：US16685632
申请日：2019-11-15
Inventor： István PUSKÁS , Lajos SZENTE , Tamas SOHAJDA
IPC: A61K31/4545 , A61K47/40
Abstract: Using sulfobutylether β-cyclodextrin a novel, physically transformed, molecularly dispersed forms lonafarnib may be prepared having pharmaceutical utility.
-
公开(公告)号：US20220152087A1
公开(公告)日：2022-05-19
申请号：US17097977
申请日：2020-11-13
Inventor： Tamas Sohajda , Istvan Puskas , Eva Harris , Francielle Tramontini Gomes de Sousa , Robert Beatty , Peter Laing
IPC: A61K31/724 , A61P9/10
Abstract: The present invention generally relates to cyclodextrin derivatives, including Dexolve®, sulfobutylether beta cyclodextrin interfering with the activity of the viral nonstructural protein NS1 produced by a flavivirus. More particularly, the present invention relates to method of treatment using cyclodextrin compounds for inhibiting or treating a condition resulting from a flavivirus infection, particularly vascular leakage condition and increased virus dissemination.
-
Patent Agency Ranking
公开(公告)号：US20220396641A1
公开(公告)日：2022-12-15
申请号：US17344217
申请日：2021-06-10
Inventor： Tamas Sohajda , Gabriella Hirschbergne Szejtli , István Puskás
Abstract: Present invention relates to a process to reduce butane sultone hydrolysis products (4-hydroxybutane-1-sulfonic acid, and bis(4-sulfobutyl) ether disodium) in sulfobutylether cyclodextrin reaction mixtures achieved with the combined use of a strong anion exchange resin having dialkyl 2-hydroxyethyl ammonium hydroxide functionality and a cation exchange resin.
-
公开(公告)号：US11649299B2
公开(公告)日：2023-05-16
申请号：US17344217
申请日：2021-06-10
Inventor： Tamas Sohajda , Gabriella Hirschbergne Szejtli , István Puskás
CPC classification number: C08B37/0012 , B01J39/05 , B01J41/05 , C08B37/0003
Abstract: Present invention relates to a process to reduce butane sultone hydrolysis products (4-hydroxybutane-1-sulfonic acid, and bis(4-sulfobutyl) ether disodium) in sulfobutylether cyclodextrin reaction mixtures achieved with the combined use of a strong anion exchange resin having dialkyl 2-hydroxyethyl ammonium hydroxide functionality and a cation exchange resin.
-
6.发明授权公开(公告)号：US11446325B2
公开(公告)日：2022-09-20
申请号：US17039483
申请日：2020-09-30
Inventor： Lajos Szente , István Puskas , Tamas Sohajda
IPC: A61K31/724 , A61P25/28
Abstract: The present invention generally relates to use of single isomer chemically modified cyclodextrins, namely, S-(carboxyalkyl)-thio-cyclodextrin salts in medication used for the prevention or treatment of lysosomal storage diseases.
More particularly, the present invention relates to isomer-pure, single isomer hexakis-S-(carboxyalkyl)-hexathio-alpha-cyclodextrin sodium salts, heptakis-S-(carboxyalkyl)-heptathio-beta-cyclodextrin sodium salts and octakis-S-(carboxyalkyl)-octathio-gamma-cyclodextrin sodium salts in medication used for the prevention or treatment of lysosomal storage diseases.-
公开(公告)号：US20220282001A1
公开(公告)日：2022-09-08
申请号：US17193247
申请日：2021-03-05
Inventor： Lajos Szente , Tamas Sohajda , István Puskás
IPC: C08B37/16 , C07C211/13
Abstract: Present invention relates to the protection of peptides and proteins against aggregation.
The process and compositions according to the invention improve protein stability in presence of cyclodextrins without establishing any covalent interactions, only by inclusion and/or electrostatic phenomena. The carbohydrate compositions provide a temporary local molecular coating on the surface of protein macromolecules, via physical glycosylation.-
8.发明申请公开(公告)号：US20220096528A1
公开(公告)日：2022-03-31
申请号：US17039483
申请日：2020-09-30
Inventor： Lajos Szente , István Puskás , Tamas Sohajda
IPC: A61K31/724 , A61P25/28
Abstract: The present invention generally relates to use of single isomer chemically modified cyclodextrins, namely, S-(carboxyalkyl)-thio-cyclodextrin salts in medication used for the prevention or treatment of lysosomal storage diseases.
More particularly, the present invention relates to isomer-pure, single isomer hexakis-S-(carboxyalkyl)-hexathio-alpha-cyclodextrin sodium salts, heptakis-S-(carboxyalkyl)-heptathio-beta-cyclodextrin sodium salts and octakis-S-(carboxyalkyl)-octathio-gamma-cyclodextrin sodium salts in medication used for the prevention or treatment of lysosomal storage diseases
-
-
-
-
-
-
-
Search Results
8
records
(took 0.017 seconds)
